IS5058A - Samverkandi súlfónýlþvagefnis-glitasónsblöndur við sykursýki - Google Patents

Samverkandi súlfónýlþvagefnis-glitasónsblöndur við sykursýki

Info

Publication number
IS5058A
IS5058A IS5058A IS5058A IS5058A IS 5058 A IS5058 A IS 5058A IS 5058 A IS5058 A IS 5058A IS 5058 A IS5058 A IS 5058A IS 5058 A IS5058 A IS 5058A
Authority
IS
Iceland
Prior art keywords
glitzone
sulphonylurea
synergistic
diabetes
preparations
Prior art date
Application number
IS5058A
Other languages
English (en)
Inventor
W. Whitcomb Randall
Original Assignee
Warner Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Company filed Critical Warner Lambert Company
Publication of IS5058A publication Critical patent/IS5058A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS5058A 1997-02-19 1999-05-27 Samverkandi súlfónýlþvagefnis-glitasónsblöndur við sykursýki IS5058A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19
PCT/US1997/021996 WO1998036755A1 (en) 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergistic combinations for diabetes

Publications (1)

Publication Number Publication Date
IS5058A true IS5058A (is) 1999-05-27

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5058A IS5058A (is) 1997-02-19 1999-05-27 Samverkandi súlfónýlþvagefnis-glitasónsblöndur við sykursýki

Country Status (29)

Country Link
US (2) US5859037A (is)
EP (1) EP0957923A1 (is)
JP (1) JP2001512478A (is)
KR (1) KR20000071179A (is)
CN (1) CN1244801A (is)
AR (1) AR011829A1 (is)
AU (1) AU741215B2 (is)
BG (1) BG103671A (is)
BR (1) BR9714505A (is)
CA (1) CA2272478A1 (is)
CZ (1) CZ289299A3 (is)
EA (1) EA199900725A1 (is)
EE (1) EE9900345A (is)
GT (1) GT199800037A (is)
HN (1) HN1997000167A (is)
HU (1) HUP0001528A3 (is)
IL (1) IL130027A (is)
IS (1) IS5058A (is)
NO (1) NO993982L (is)
NZ (1) NZ336002A (is)
PA (1) PA8447401A1 (is)
PE (1) PE74399A1 (is)
PL (1) PL335166A1 (is)
SK (1) SK111899A3 (is)
SV (1) SV1998000010A (is)
TR (1) TR199902033T2 (is)
UY (1) UY24893A1 (is)
WO (1) WO1998036755A1 (is)
ZA (1) ZA981343B (is)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
EP1787646A3 (en) * 1997-06-18 2007-10-03 Smithkline Beecham Plc Novel method of treatment
DE69837089T2 (de) * 1997-06-18 2007-06-21 Smithkline Beecham P.L.C., Brentford Behandlung der diabetes mit thiazolidindion und sulfonylharnstoff
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6417185B1 (en) 1998-06-19 2002-07-09 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
RU2227749C2 (ru) * 1998-12-24 2004-04-27 Метабэйсис Терапьютикс, Инк. Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
US6617122B1 (en) * 1999-03-15 2003-09-09 Xenon Genetics, Inc. Process for identifying modulators of ABC1 activity
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
ATE266409T1 (de) 2000-04-13 2004-05-15 Pfizer Prod Inc Synergistische wirkung von glyburide und milrinone
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20120034211A (ko) 2002-09-20 2012-04-10 안드렉스 랩스 엘엘씨 약제학적 정제
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
GEP20084570B (en) 2003-10-31 2008-12-25 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Combined drug for treating diabetes
WO2007028633A2 (en) * 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
AU2006289259A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
AU2006328328B2 (en) 2005-12-22 2012-08-30 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
WO2008026668A1 (en) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Medicinal composition containing insulin resistance improving agent
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 fgf-21 폴리펩티드 및 그 용도
JP5812318B2 (ja) 2007-12-04 2015-11-11 レメディー ファーマシューティカルズ, インコーポレイテッド 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
RU2630577C2 (ru) * 2008-12-04 2017-09-11 Чунси ЮЙ Композиции интенсивного проникновения и их применение
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
CN102655866B (zh) * 2009-11-13 2013-11-13 东丽株式会社 糖尿病的治疗或预防药
US9241952B2 (en) 2010-05-24 2016-01-26 Ozstar Therapeutics Pty Ltd Method of treating type II diabetes, hyperglycemia or hypoglycemia by administering a synergistic combination of a sulphonylurea and inulin
EP2665433B1 (en) 2011-01-19 2021-03-10 Fractyl Laboratories Inc. Devices for the treatment of tissue
RU2642633C2 (ru) 2011-11-23 2018-01-25 Озстар Терапьютикс Пти Лтд Улучшенные синергические противодиабетические композиции
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
WO2013130655A1 (en) 2012-02-27 2013-09-06 Fractyl Laboratories, Inc. Heat ablation systems, devices and methods for the treatment of tissue
JP6235559B2 (ja) 2012-04-19 2017-11-22 フラクティル ラボラトリーズ インコーポレイテッド 組織拡張デバイス、システムおよび方法
EP3714826A1 (en) 2012-07-30 2020-09-30 Fractyl Laboratories, Inc. Electrical energy ablation systems and devices for the treatment of tissue
WO2014026055A1 (en) 2012-08-09 2014-02-13 Fractyl Laboratories Inc. Ablation systems, devices and methods for the treatment of tissue
WO2014055997A1 (en) 2012-10-05 2014-04-10 Fractyl Laboratories Inc. Methods, systems and devices for performing multiple treatments on a patient
WO2014197632A2 (en) 2013-06-04 2014-12-11 Fractyl Laboratories, Inc. Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
US11986235B2 (en) 2013-09-12 2024-05-21 Fractyl Health, Inc. Systems, methods and devices for treatment of target tissue
JP6603660B2 (ja) 2013-11-22 2019-11-06 フラクティル ラボラトリーズ インコーポレイテッド 消化管における治療制約の生成のためのシステム、デバイスおよび方法
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US9757535B2 (en) 2014-07-16 2017-09-12 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
WO2016011269A1 (en) 2014-07-16 2016-01-21 Fractyl Laboratories, Inc. Methods and systems for treating diabetes and related diseases and disorders
BR112017008157A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co polipeptídeos de fgf-21 modificados e usos dos mesmos
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
WO2021102423A1 (en) * 2019-11-22 2021-05-27 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
US12350264B2 (en) 2019-11-22 2025-07-08 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder
IL294671A (en) 2020-01-15 2022-09-01 Fractyl Health Inc Automated tissue handling devices, systems and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
US5972973A (en) 1999-10-26
TR199902033T2 (xx) 2000-02-21
BR9714505A (pt) 2000-03-21
SV1998000010A (es) 1999-02-02
PA8447401A1 (es) 2001-12-14
EE9900345A (et) 2000-02-15
WO1998036755A1 (en) 1998-08-27
NO993982D0 (no) 1999-08-18
CN1244801A (zh) 2000-02-16
SK111899A3 (en) 2000-09-12
EA199900725A1 (ru) 2000-04-24
NZ336002A (en) 2002-03-28
NO993982L (no) 1999-08-18
ZA981343B (en) 1998-11-16
AR011829A1 (es) 2000-09-13
KR20000071179A (ko) 2000-11-25
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28
BG103671A (en) 2000-04-28
PE74399A1 (es) 1999-08-20
AU5590898A (en) 1998-09-09
AU741215B2 (en) 2001-11-29
HUP0001528A3 (en) 2000-12-28
HN1997000167A (es) 1999-02-09
IL130027A0 (en) 2000-02-29
CA2272478A1 (en) 1998-08-27
PL335166A1 (en) 2000-04-10
UY24893A1 (es) 1998-07-10
JP2001512478A (ja) 2001-08-21
US5859037A (en) 1999-01-12
IL130027A (en) 2005-09-25
EP0957923A1 (en) 1999-11-24
CZ289299A3 (cs) 1999-11-17

Similar Documents

Publication Publication Date Title
NO993982D0 (no) Synergistiske sulfonylurea-glitazone-kombinasjoner for diabetes
DK0921796T3 (da) Tetrahydrolipstatinholdige præparater
IS5425A (is) Læknislyf
NO2006014I1 (no) Insulin glulisin
DE69825982D1 (de) Spritze
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
IS5953A (is) Lyfjablöndur úr örgerðum eplerenonum
NO995712D0 (no) Oftalmiske preparater
DE69827328D1 (de) Vormontierte Spritze
ATE266383T1 (de) Dermatologische zubereitungen
NO980546D0 (no) Farmasöytiske midler
NO20000231D0 (no) Dolastatin-15-derivater
NO20001494L (no) Overligger
NO995251D0 (no) FremgangsmÕte for administrering av haloterapi
ID21009A (id) Komposisi untuk supositori
DE59707298D1 (de) Desodorierende zubereitungen
DE69926012D1 (de) Arzneizubereitungen
NO994619D0 (no) Farmasöytiske blandinger
ATE246494T1 (de) Brausezubereitungen
NO20003141D0 (no) Farmasøytiske blandinger
DK0862850T3 (da) Mejetærsker
DE69906934D1 (de) Arzneizubereitungen
IT246279Y1 (it) Guarnitura per mobili
NO993354D0 (no) Voksholdige preparater
EP1142589A4 (en) Medicinal preparations